{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T11:50:18Z","timestamp":1777981818911,"version":"3.51.4"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"crossref","award":["RSP2023R131"],"award-info":[{"award-number":["RSP2023R131"]}],"id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>Torasemide is a potassium-sparing loop diuretic used to treat fluid retention associated with congestive heart failure and kidney and hepatic diseases. This systematic review was conducted to combine all accessible data on the pharmacokinetics (PK) of torasemide in healthy and diseased populations, which may help clinicians avert adverse drug reactions and determine the correct dosage regimen.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Four databases were systematically searched to screen for studies associated with the PK of torasemide, and 21 studies met the eligibility criteria. The review protocol was registered in the PROSPERO database (CRD42023390178).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A decrease in maximum plasma concentration (C<jats:sub>max<\/jats:sub>) was observed for torasemide after administration of the prolonged-release formulation in comparison to that after administration of the immediate-release formulation, that is, 1.12 \u00b1 0.17 versus 1.6 \u00b1 0.2 mcg\/mL. After administering an oral dose of torasemide, a 2-fold increase in the area under the concentration\u2013time curve (AUC) was reported in patients with congestive heart failure compared with the healthy population. Moreover, the patients with renal failure (clearance &lt; 30 mL\/min) showed an increase in value of AUC<jats:sub>0\u2013\u221e<\/jats:sub> that is, 42.9 versus 8.091 mcg.h<jats:sup>\u22121<\/jats:sup>.mL<jats:sup>\u22121<\/jats:sup> compared with healthy subjects. In addition, some studies have reported interactions with different drugs, in which irbesartan showed a slight increase in the AUC<jats:sub>0\u2013\u221e<\/jats:sub> of torasemide, whereas losartan and empagliflozin did not.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The current review summarizes all available PK parameters of torasemide that may be beneficial for avoiding drug\u2013drug interactions in subjects with renal and hepatic dysfunction and for predicting doses in patients with different diseases.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001141","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T02:00:28Z","timestamp":1704420028000},"page":"309-320","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["A Systematic Critical Review of Clinical Pharmacokinetics of Torasemide"],"prefix":"10.1097","volume":"46","author":[{"given":"Abdul Wasay","family":"Sherazi","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammara","family":"Zamir","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anees ur","family":"Rehman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waseem","family":"Ashraf","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imran","family":"Imran","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Saeed","sequence":"additional","affiliation":[{"name":"University College of Pharmacy, University of the Punjab, Lahore, Pakistan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdul","family":"Majeed","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zikria","family":"Saleem","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faleh","family":"Alqahtani","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8607-8583","authenticated-orcid":false,"given":"Muhammad Fawad","family":"Rasool","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,1,1]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fvets.2020.00151","article-title":"Population pharmacokinetics and pharmacodynamics modeling of torasemide and furosemide after oral repeated administration in healthy Dogs","volume":"7","author":"Pelligand","year":"2020","journal-title":"Front Vet Sci"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/ajhp\/52.16.1771","article-title":"Torsemide: a new loop diuretic","volume":"52","author":"Fowler","year":"1995","journal-title":"Am J Health Syst Pharm"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1211\/jpp.58.11.0008","article-title":"Classification of torasemide based on the Biopharmaceutics Classification System and evaluation of the FDA biowaiver provision for generic products of CLASS I drugs","volume":"58","author":"Khan","year":"2006","journal-title":"J Pharm Pharmacol"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1177\/106002809502900411","article-title":"Torsemide: a pyridine-sulfonylurea loop diuretic","volume":"29","author":"Blose","year":"1995","journal-title":"Ann Pharmacother"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.clpt.2004.08.024","article-title":"CYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide","volume":"76","author":"Vormfelde","year":"2004","journal-title":"Clin Pharmacol Ther"},{"issue":"suppl 3","key":"R6-20250603","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00003495-199100413-00005","article-title":"The loop diuretic torasemide in chronic renal failure. Pharmacokinetics and pharmacodynamics","volume":"41","author":"Knauf","year":"1991","journal-title":"Drugs"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"100104","DOI":"10.1016\/j.jics.2021.100104","article-title":"Ruthenium (III) catalysed and uncatalysed oxidation of torsemide by hexacyanoferrate (III) in aqueous alkaline medium: a kinetic comparative approach","volume":"98","author":"Ravindra","year":"2021","journal-title":"J Indian Chem Soc"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1556\/JPC.27.2014.4.10","article-title":"Simultaneous estimation of amiloride hydrochloride and torsemide in their combined dosage forms by high-performance thin-layer chromatography","volume":"27","author":"Bhadja","year":"2014","journal-title":"J Planar Chromatogr"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jacc.2018.10.075","article-title":"Use of medication for cardiovascular disease during pregnancy: JACC state-of-the-art review","volume":"73","author":"Halpern","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-199834010-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of torasemide","volume":"34","author":"Knauf","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10741-020-10003-7","article-title":"Comparative effects of furosemide and other diuretics in the treatment of heart failure: a systematic review and combined meta-analysis of randomized controlled trials","volume":"26","author":"Eid","year":"2021","journal-title":"Heart Fail Rev"},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/jep.13261","article-title":"Torasemide versus furosemide in treatment of heart failure: a systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Sherif","year":"2020","journal-title":"J Eval Clin Pract"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.amjcard.2019.09.039","article-title":"Meta-analysis comparing torsemide versus furosemide in patients with heart failure","volume":"125","author":"Abraham","year":"2020","journal-title":"Am J Cardiol"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2217\/fca.12.54","article-title":"Should torsemide be the loop diuretic of choice in systolic heart failure?","volume":"8","author":"DiNicolantonio","year":"2012","journal-title":"Future Cardiol"},{"key":"R17-20250603","first-page":"60","article-title":"Loop diuretics in the management of acute renal failure: a systematic review and meta-analysis","volume":"9","author":"Bagshaw","year":"2007","journal-title":"Crit Care Resusc"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10741-019-09771-8","article-title":"READY: relative efficacy of loop diuretics in patients with chronic systolic heart failure-a systematic review and network meta-analysis of randomised trials","volume":"24","author":"T\u00e4ger","year":"2019","journal-title":"Heart Fail Rev"},{"key":"R19-20250603","first-page":"Cd010138","article-title":"Loop diuretics for patients receiving blood transfusions","volume":"2015","author":"Sarai","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2459\/JCM.0000000000000794","article-title":"Torsemide versus furosemide and intermediate-term outcomes in patients with heart failure: an updated meta-analysis","volume":"20","author":"Miles","year":"2019","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg (London, England)"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1460-9592.2008.02918.x","article-title":"Are peripheral and neuraxial blocks with ultrasound guidance more effective and safe in children?","volume":"19","author":"Rubin","year":"2009","journal-title":"Paediatric Anaesth"},{"key":"R24-20250603","first-page":"31","article-title":"Optimising the value of the critical appraisal skills programme (CASP) tool for quality appraisal in qualitative evidence synthesis","volume":"1","author":"Long","year":"2020","journal-title":"Res Methods Med Health Sci"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1007\/s11096-022-01390-y","article-title":"The use of a modified Delphi technique to develop a critical appraisal tool for clinical pharmacokinetic studies","volume":"44","author":"Soliman","year":"2022","journal-title":"Int J Clin Pharm"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/jcpt.13764","article-title":"Clinical pharmacokinetics of nadolol: a systematic review","volume":"47","author":"Kalsoom","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s40262-022-01145-y","article-title":"Clinical pharmacokinetics of metoprolol: a systematic review","volume":"61","author":"Zamir","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jclinepi.2012.09.016","article-title":"Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity","volume":"66","author":"Kim","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"suppl l","key":"R30-20250603","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00541464","article-title":"Torasemide, a new potent diuretic. Double-blind comparison with furosemide","volume":"31","author":"Broekhuysen","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/clpt.1987.131","article-title":"Clinical pharmacology of torasemide, a new loop diuretic","volume":"42","author":"Brater","year":"1987","journal-title":"Clin Pharmacol Ther"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/BF00315407","article-title":"Pharmacokinetics of torasemide and its metabolites in healthy controls and in chronic renal failure","volume":"39","author":"Spahn","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/jps.2600790520","article-title":"Solid-phase extraction and liquid chromatography of torsemide and metabolites from plasma and urine","volume":"79","author":"March","year":"1990","journal-title":"J Pharm Sci"},{"issue":"suppl 1","key":"R34-20250603","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00877960","article-title":"Pharmacokinetics and pharmacodynamics of torasemide in patients with chronic renal insufficiency: a preliminary evaluation","volume":"7","author":"Brater","year":"1993","journal-title":"Cardiovasc Drugs Ther"},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/clpt.1993.116","article-title":"Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis","volume":"54","author":"Schwartz","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/clpt.1994.98","article-title":"The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency","volume":"56","author":"Gehr","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF00194966","article-title":"Pharmacokinetics of torasemide and its metabolites in end-stage renal disease","volume":"47","author":"Kr\u00e4mer","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/0009-9236(95)90222-8","article-title":"Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure","volume":"57","author":"Vargo","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0168-8278(96)80207-8","article-title":"Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites","volume":"25","author":"Gentilini","year":"1996","journal-title":"J Hepatol"},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0002-9343(98)00111-9","article-title":"The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure","volume":"104","author":"Gottlieb","year":"1998","journal-title":"Am J Med"},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/j.1552-4604.1998.tb04810.x","article-title":"Pharmacokinetics of torsemide in patients with decompensated and compensated congestive heart failure","volume":"38","author":"Bleske","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2165\/00003088-200847050-00003","article-title":"Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers","volume":"47","author":"Werner","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1440-1681.2008.05089.x","article-title":"A bioavailability\/bioequivalence and pharmacokinetic study of two oral doses of torasemide (5 and 10 mg): prolonged-release versus the conventional formulation","volume":"36","author":"Barbanoj","year":"2009","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1472-8206.2008.00643.x","article-title":"Comparison of repeated-dose pharmacokinetics of prolonged-release and immediate-release torasemide formulations in healthy young volunteers","volume":"23","author":"Barbanoj","year":"2009","journal-title":"Fundam Clin Pharmacol"},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/0091270009337514","article-title":"Gender is an important determinant of the disposition of the loop diuretic torasemide","volume":"50","author":"Werner","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/cpt.258","article-title":"Heritability of metoprolol and torsemide pharmacokinetics","volume":"98","author":"Matthaei","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clinthera.2014.12.018","article-title":"Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study","volume":"37","author":"Heise","year":"2015","journal-title":"Clin Ther"},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"e006135","DOI":"10.1161\/JAHA.117.006135","article-title":"Sodium and fluid excretion with torsemide in healthy subjects is limited by the short Duration of diuretic action","volume":"6","author":"Shah","year":"2017","journal-title":"J Am Heart Assoc"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:12:43Z","timestamp":1748970763000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001141","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,1]]},"assertion":[{"value":"2023-02-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}